127 related articles for article (PubMed ID: 20801030)
1. Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.
Richter HG; Freichel C; Huwyler J; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Roche O; Schuler F; Taylor S; Ullmer C; Wiegand R
Bioorg Med Chem Lett; 2010 Oct; 20(19):5713-7. PubMed ID: 20801030
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.
Tao M; Aimone LD; Gruner JA; Mathiasen JR; Huang Z; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(2):1073-7. PubMed ID: 22197136
[TBL] [Abstract][Full Text] [Related]
4. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.
Hudkins RL; Zulli AL; Dandu Rr; Tao M; Josef KA; Aimone LD; Haltiwanger RC; Huang Z; Lyons JA; Mathiasen JR; Raddatz R; Gruner JA
Bioorg Med Chem Lett; 2012 Feb; 22(4):1504-9. PubMed ID: 22290075
[TBL] [Abstract][Full Text] [Related]
5. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L
ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
[TBL] [Abstract][Full Text] [Related]
7. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
[TBL] [Abstract][Full Text] [Related]
8. 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
Pierson PD; Fettes A; Freichel C; Gatti-McArthur S; Hertel C; Huwyler J; Mohr P; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Richter H; Roche O; Rodríguez Sarmiento RM; Schmitt M; Schuler F; Takahashi T; Taylor S; Ullmer C; Wiegand R
J Med Chem; 2009 Jul; 52(13):3855-68. PubMed ID: 19456097
[TBL] [Abstract][Full Text] [Related]
9. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
11. 1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H
Shinde AK; Badange RK; Reballi V; Achanta PK; Bojja K; Manchineella S; Rao Muddana N; Subramanian R; Choudary Palacharla R; Benade V; Jayarajan P; Thentu JB; Lingavarapu BB; Yarra S; Kagita N; Rao Doguparthi M; Mohammed AR; Nirogi R
ChemMedChem; 2022 Feb; 17(3):e202100583. PubMed ID: 34761873
[TBL] [Abstract][Full Text] [Related]
12. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
[TBL] [Abstract][Full Text] [Related]
14. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
[No Abstract] [Full Text] [Related]
15. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
[TBL] [Abstract][Full Text] [Related]
16. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.
Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER
Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432
[TBL] [Abstract][Full Text] [Related]
17. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
18. High constitutive activity of native H3 receptors regulates histamine neurons in brain.
Morisset S; Rouleau A; Ligneau X; Gbahou F; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
Nature; 2000 Dec; 408(6814):860-4. PubMed ID: 11130725
[TBL] [Abstract][Full Text] [Related]
19. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.
Hamill TG; Sato N; Jitsuoka M; Tokita S; Sanabria S; Eng W; Ryan C; Krause S; Takenaga N; Patel S; Zeng Z; Williams D; Sur C; Hargreaves R; Burns HD
Synapse; 2009 Dec; 63(12):1122-32. PubMed ID: 19670309
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
Schneider EH; Strasser A; Thurmond RL; Seifert R
J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
